Purchase this article with an account.
Jessica V Jasien, Alon Skaat, Robert Ritch; Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% Efficacy in Patients with Exfoliation Syndrome (XFS) and Ocular Hypertension (OHT) or Exfoliative Glaucoma (XFG). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5713.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Elevated intraocular pressure (IOP) is the sole proven modifiable risk factor for XFG development and progression. Rho-associated protein kinase inhibitors have been studied for their ability to lower IOP, by several mechanisms including disruption of adhesions between the trabecular meshwork (TM) cells and increasing aqueous outflow. The main purpose of this study was to evaluate the efficacy of AR-12286 and evaluate the lasting effect on IOP after discontinuation.
Double-blind, interventional study, study eye of 6 men and 4 women was randomized to AR-12286 0.5% or 0.7% adjunctive to current IOP lowering regimen for 6 months. Visits included baseline, 1 week, 1 and 3 months; at 3 months AR-12286 was discontinued for one week and was resumed at week 13. At the 6 month visit, AR-12286 was discontinued, with final visit at week 25.
The study eye mean baseline IOP was 25±2.4mmHg, mean IOP reduced to 19.1±2.3 mmHg at 1 week (P<0.001), 17.5±3.6 mmHg at 1 month (P<0.001), and 17.4±3.6 mmHg at 3 months (P<0.001), yielding an average IOP reduction of 26.8%, 35.3% and 35.8% respectively. At the 13 week visit, after AR-12286 was discontinued, mean IOP increased to 21.6±5.4 mmHg (P=0.06 compared to baseline). At 6 months, the mean IOP was 21.8±7.8 mmHg (P=0.2), and AR-12286 was discontinued. At week 25 the mean IOP was 21.3±5.3 mmHg (P=0.06).
AR-12286 was well tolerated and provided clinically statistical significant ocular hypotensive efficacy with XFS and OHT or XFG patients. This drug may represent a new therapeutic paradigm for the treatment of XFG.
This PDF is available to Subscribers Only